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The class II transactivator (CIITA) is induced by gamma interferon (IFN-) and activates major histocom-
patibility complex class II; however, this report shows it suppresses other genes. An N-terminal 36 amino acids
of CIITA mediates suppression of the collagen 2(I) promoter via binding to CREB-binding protein (CBP).
Reconstitution of cells with CBP reverts this suppression. IFN- is known to inhibit collagen gene expression;
to test if CIITA mediates this gene suppression, a mutant cell line defective in CIITA induction but not in the
activation of STAT1/JAK/IRF-1 is studied. IFN- suppression of the collagen promoter and the endogenous
gene is observed in the wild-type control but not in the mutant line. Suppression is restored when CIITA is
introduced. Other targets of CIITA-mediated promoter suppression include interleukin 4, thymidine kinase,
and cyclin D1.
The class II transactivator (CIITA) is a master regulator of
major histocompatibility complex class II (MHC-II), Ii, and
DM genes (8, 9, 10, 55, 56). CIITA was initially identified by
complementation of an HLA-DR mutant B-cell line, RJ2.2.5
(55), which was created by mutagenesis followed by negative
immunoselection for MHC-II-defective cells (1). CIITA is im-
portant for the constitutive expression of MHC-II in B cells
and dendritic cells and the cytokine induction of these genes in
a variety of other cell types. Gamma interferon (IFN-) is a
prime example of a cytokine which induces CIITA and subse-
quently MHC-II expression.
CIITA is a transcriptional coactivator that does not bind
DNA (55) but does interact with RFX (consisting of RFX5-
RFXANK-RFXAP), CREB, and NF-Y (NF-YA/B/C) (65), all
of which directly bind to the X and Y element of the MHC-II
promoters. Specifically, CIITA interacts with both RFX5 and
RFXANK and NF-YB and NF-YC but not with NF-YA. In
addition, CIITA also interacts with the histone acetyltrans-
ferase (HAT) CREB-binding protein (CBP) (20, 30), which
can acetylate histone at lysine residues to allow gene activation
(13, 19, 31, 57, 59, 62). Thus, CIITA appears to be a focal point
of interaction for both DNA-binding proteins specific for the
MHC-II promoters and for HATs to allow chromatin opening.
CIITA expression is strongly induced by IFN- (56). Two of
its promoters, promoter III and promoter IV, are responsible
for IFN- inducibility (39, 42, 43). Promoter III contains a
proximal sequence that is responsible for the constitutive ex-
pression of CIITA in B cells and a distal sequence containing
STAT1-responsive element which confers IFN- responsive-
ness. Promoter IV contains the major IFN-responsive se-
quence regulated by both STAT1 and IRF-1.
An invaluable tool to study IFN- pathways has been the use
of mutant cell lines. Mutant lines which are defective in the
IFN- induction of MHC-II genes but not defective in the
induction of other IFN- functions have been useful in eluci-
dating this pathway (9, 37). The G3A cell line was derived from
the commonly used IFN--responsive parental cell line 2fTGH
(10). IFN- treatment of G3A cells causes the normal induc-
tion of most responsive genes but causes a selective failure to
induce MHC-II, Ii, and DM. This is caused by a defect in the
IFN induction of CIITA and places CIITA downstream of the
JAK/STAT pathway.
In addition to its well-known function in inducing gene ex-
pression, IFN- also suppresses the expression of a number of
genes. There are several examples of IFN--suppressible pro-
moters or genes, and these can be loosely grouped as the
following: genes important for cell proliferation and cell dif-
ferentiation, such as cyclin (51) and c-myc and N-myc (59);
certain cytokine genes expressed by the TH2 subpopulation,
such as interleukin 4 (IL-4) (15) and IL-10 (17); and genes
coding for matrix proteins, such as the collagen (26, 29, 58) and
proteoglycan (16, 50) genes. The mechanism by which IFN-
causes gene suppression is not well known, and the present
study shows that one mechanism involves the CIITA molecule.
The rationale for this study stems from a previous report,
where we and others detected interactions of CIITA with a
number of DNA-binding proteins that bind the MHC-II pro-
moters (65). This prompted us to determine if CIITA can
selectively induce the expression of MHC-II but simulta-
neously sequester DNA-binding proteins from their other gene
targets. The squelching of transcription factors has been pro-
posed before (4, 21, 34, 43); however, there are few good
physiologic examples of squelching. In this report, we deter-
mined that CIITA can squelch the expression of NF-Y-depen-
dent promoters. However, this was not reversed by the addi-
tion of NF-Y, and the CIITA domain that is required for this
effect does not match the CIITA–NF-Y interaction site. In-
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stead, the region within CIITA that is required for squelching
maps to a 36-amino-acid (aa) region which binds the CBP.
Significantly, squelching was observed under biologic condi-
tions where the effects of endogenous CIITA on endogenous
collagen gene expression were examined. These experiments
show that this small peptide domain is a potent inhibitor of
CBP function and elucidate a possible mechanism by which
IFN- suppresses gene expression.
MATERIALS AND METHODS
Cell cultures. NIH 3T3 cells were maintained in Dulbecco’s modified Eagle
medium (DMEM) (Sigma) supplemented with 10% Colorado calf serum (Col-
orado Serum Company). 2fTGH and G3A cells were cultured in DMEM (Sig-
ma) supplemented with 10% fetal bovine serum (FBS) as previously described
(10). Cells were grown in an incubator at 37°C and 5% CO2.
Plasmid constructs. The PCR-amplified collagen 2(I) promoter from 357
to 55 bp (48) was introduced into pGL3-CAT basic and pGL3-luciferase basic
vectors (Promega) at the EcoRV cloning site. The orientation was checked by
restriction digestion and direct DNA sequencing. pGL3-DRA-CAT and pGL3-
DRA-Luc reporter constructs bear 300 bp of the DRA promoter (10, 11).
IL-4–chloramphenicol acetyltransferase (CAT) (32) and TK-CAT (7) were
kindly provided by M. Li-Weber, German Cancer Research Center, Heidelberg,
Germany. CD1-Luc was a generous gift from Albert Baldwin’s Lab, UNC
Lineberger Cancer Center (24). For mutagenesis studies FlagCIITA (11) was
used as a parent template, and stop codons were introduced at residue position
335 to generate FlagCIITA(1-335) using the QuickChange mutagenesis protocol
(Stratagene). FlagCIITA(1-297), FlagCIITA(1-251), FlagCIITA(1-215), FlagCI-
ITA(1-177), FlagCIITA(1-139), FlagCIITA(1-94), and FlagCIITA(1-58) were
constructed using FlagCIITA as a template together with a common upper-
strand primer, GACCCAAAGCTTGGTACCGAG, that is contained in
pcDNA3 and a series of lower-strand primers that distribute along the human
CIITA sequences at the designated positions. CIITA(334-1130) was generated
by introducing a BglI site into FlagCIITA using the Stratagene QuickChange
protocol and inserting the BglII-EcoRI fragment into the BglII-EcoRI-digested
pcDNA3HisC expression vector (Invitrogen). CIITA(59-94) was generated by
overlapping PCR by standard procedure using pcDNA3.1FlagCIITA as template
with the following primers: (i) 5 GGCGTGTACGGTGGGAGGTC (on
pcDNA3.1), (ii) 5 CCAGTTCCGCGATATTGGCATATCCAGCCAGGTCC
TACTGGTC, (iii) 5 GACCAGATGGACCTGGCTGGATATGCCAATATC
GCGGAACTGG, and (iv) 5 TGGTGGGGACAAACTGGATGGG. The PCR
products of primers i and ii and primers iii and iv were combined and subjected
to a second-round PCR using primers i and iv. The fused PCR product was
reintroduced into pcDNA3.1FlagCIITA at NheI and Bsu36I sites. FlagNF-YA,
FlagNF-YB, and FlagNF-YC have been previously described (65) and consist of
a full-length gene coding for an individual NF-Y subunit tagged at the 5 end with
the Flag sequence. CMV5-CBP was kindly provided by R. H. Goodman, Vollum
Institute, Oregon Health Science University (13). All plasmids were purified
using a Qiagen column (Qiagen).
Transient transfection and CAT and/or luciferase assay. Ninety thousand to
1.2  105 NIH 3T3 cells or 1.5  105 2fTGH or G3A cells were plated in 6-well
plates (Fisher) and cultured for 18 h before transfection. One microgram or
various amounts (as described in the text or in the figure legends) of reporter
plasmid was cotransfected with 1.0 g or various amounts (as described in the
text or in the figure legends) of expression vector or its empty vector. Transfected
cells were incubated with or without 500 U of IFN-/ml. Cells were harvested
48 h later and assayed for CAT and/or luciferase activity (Promega) following
standard procedures (10, 43) with the same amount of protein as determined by
the Bradford protein assay (Bio-Rad).
Immunoprecipitation and Western blot analyses of in vivo protein-protein
interaction. COS7 cells were cultured in a 37°C incubator with 5% CO2 in
DMEM (Sigma) supplemented with 10% FBS. Cells were plated at 9  105
cells/100-mm-diameter dish and allowed to grow for 18 h. Cells were cotrans-
fected with 3 g of each plasmid as described in the figure legend for each
experiment using Fugene 6 (Boehringer Mannheim) and following the manu-
facturer’s instructions. After 30 to 40 h of culture, cells were washed twice with
1 phosphate-buffered saline and lysed with 1.5 ml of cold radioimmunopre-
cipitation assay (RIPA) buffer (49) (0.1% sodium dodecyl sulfate [SDS], 1%
NP-40, 1% deoxycholate, 150 mM NaCl, 2 mM EDTA, 0.01 M sodium phos-
phate [pH 7.2], and 50 mM NaF) supplemented with a tablet of Complete
protease inhibitor cocktail (Boehringer Mannheim) per 50 ml of solution. Im-
munoprecipitation and Western blotting were performed following standard
procedures (47, 49, 54). Blots were detected by ECL (Pierce) using Kodak
X-OMAT film. Detailed information is available upon request.
Total RNA isolation and RT-PCR. Total RNA was extracted from the culture
cells with the RNeasy mini-total RNA isolation kit (Qiagen) according to the
manufacturer’s instruction. The primers used for reverse transcriptase (RT)-
PCR are as follows: for human collagen 2(I), 5 GACTCAGCCACCCAGAG
TGG and 5 TGGTCAGCACCACCGATGTCC, which gave a 440-bp band; for
human glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 5 GAGGGGC
CATCCACAGTCTTC and 5 CAAAAGGGTCATCATCTCTGC, which gave a
228-bp band. RT-PCR was performed using Access RT-PCR System (Promega)
according to the manufacturer’s instructions. One microgram of total RNA was
used for each reaction and was subjected to 20 to 30 cycles of amplification. The
linear phase of the amplification process was first determined for each primer set
and then was used in all the experiments. Ten microliters of RT-PCR product
was subjected to 1.5% agarose gel electrophoresis and stained with ethidium
bromide for visualization and digital recording. One and a half micrograms of
total RNA was reverse transcribed with Moloney murine leukemia virus reverse
transcriptase (Gibco-BRL) in 50 l of reaction mixture, and 3 l of each reaction
mixture was subjected to PCR amplification in the presence of 5 Ci of
[-32P]dCTP using primers 5 CCTTACTGGTGCCAAGGGTGCTG and 5
CCAGGGAATCCAATGTTGCCA, which yield a 577-bp product. As a positive
control, samples of cDNA were also amplified in parallel with a pair of human
GAPDH-specific primers, which yield a 220-bp product. Ten or 20 l of the PCR
mixtures were fractionated on a nondenatured polyacrylamide gel, visualized by
autoradiography with Kodak X-ray film, and quantitated with NIH Image soft-
ware (National Institutes of Health).
RESULTS
CIITA inhibits the transcriptional activation of the collagen
promoter which contains an NF-Y binding site. A previous
report shows that CIITA directly binds to the NF-Y protein
(65). One hypothesis is that CIITA may serve as a scaffolding
protein that binds NF-Y and enriches its local concentration at
the site of an MHC-II promoter. Accordingly, less NF-Y would
be available for the transcription of other promoters. To ex-
amine this possibility, we determined if CIITA can inhibit
promoters containing an NF-Y binding site. Two of the clas-
sical promoters which originally defined the NF-Y/CBF cog-
nate binding site are those of MHC-II and collagen 2(I) (5,
18, 35, 36). To determine if CIITA can inhibit the activation of
the collagen promoter, we cotransfected NIH 3T3 cells with a
collagen 2(I) promoter CAT reporter construct (col-CAT)
and increasing amounts of a CIITA expression plasmid (Fig.
1A) (14). CIITA inhibited col-CAT transcription activity in a
dose-dependent manner (lanes 3 to 6) until the activity was
extinguished. The process of inhibition could take place in the
nucleus, as CIITA linked to a strong nuclear localization se-
quence (NLS) from simian virus 40 produced efficient suppres-
sion of col-CAT activity (compare lanes 7 and 4). This CIITA-
NLS construct is expressed almost exclusively in the nucleus
(data not shown). In the same cell where the suppression of
col-CAT activity was observed (Fig. 1B, left panel), CIITA
activated DRA-promoter-driven luciferase reporter expression
(Fig. 1B, right panel). Thus, CIITA has dual effects: the sup-
pression of a collagen promoter and the activation of an
MHC-II promoter.
The inhibition of the collagen promoter by CIITA is not
reversed by the addition of NF-Y proteins. As described ear-
lier, one of the premises for this study is the assumption that
CIITA interacts with NF-Y proteins, thereby reducing their
availability for the transcription of other promoters. If this
were the case, the introduction of NF-Y expression vectors
should overcome this sequestration. The collagen promoter
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activity was reduced by the presence of CIITA as described
earlier (compare lanes 1 and 2 in Fig. 2A, panels a, b, c, and d).
The addition of NF-YA had no positive effect on the collagen
promoter (Fig. 2A, panel a, compare lane 2 to lanes 3 and 4).
The addition of NF-YB resulted in a modest restoration of
promoter activity (Fig. 2A, panel b, compare lane 2 to lanes 3
and 4), and the addition of NF-YC had less effect (Fig. 2A,
panel c, compare lane 2 to lanes 3 and 4). The addition of all
three NF-Y subunits together also had a minor effect (Fig. 2A,
panel d). In all these experiments, the optimal results with the
optimal quantities of NF-Y subunits are shown. This suggests
that the direct sequestering of NF-Y is unlikely the primary, or
only, mechanism for CIITA-mediated gene suppression. To
verify that NF-Y proteins were expressed, lysates were isolated
FIG. 1. CIITA inhibits the collagen promoter in a dose-dependent
manner. NIH 3T3 cells (1.1  105) were plated in a 6-well dish 18 h
before transfection. (A) Collagen 2(I) CAT reporter gene (col-CAT)
or an empty vector, pGL3-CAT, was transiently cotransfected with
various amounts of CIITA or with an empty vector, pcDNA3. Cells
were harvested 48 h later, and extracts were assayed for activity. A
representative of three experiments is shown. The CAT activities were
normalized based on the activity detected in the pGL3-CAT basic
group. Error bars represent means 	 standard errors. CIITA-NLS is
the CIITA molecule with a simian virus 40 NLS at its C-terminal end.
(B) The same cells were cotransfected with CIITA, col-CAT, and
DRA-Luc reporter constructs. col-CAT monitors the effect of CIITA
on the collagen promoter, and DRA-luc monitors the effect of CIITA
on the DRA promoter. The panel on the left shows CAT activity, while
the panel on the right shows luciferase activity. Experiments were
repeated three times.
FIG. 2. The addition of NF-Y subunits does not reverse CIITA-
mediated suppression of the collagen 2(I) promoter. (A) The four
panels show that the addition of exogenous NF-YA, NF-YB, NF-YC,
or a combination of the three had little to modest effects on CIITA-
mediated suppression of the collagen promoter. The NF-Y subunits,
alone or in combination, were examined for their capacity to reverse
CIITA-mediated suppression of the collagen promoter. All the exper-
iments were repeated three times. (B) The expression of NF-YA,
NF-YB, and NF-YC in COS7 cell transfectants was confirmed by
immunoblotting (IB) using anti-Flag M5 antibody.
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from cells that were separately transfected with NF-YA, NF-
YB, or NF-YC. A Western analysis was performed, and it
showed the robust expression of these proteins (Fig. 2B).
Inhibition of collagen 2(I) promoter activity by CIITA re-
quires the N-terminal 59 to 94 aa of CIITA. To elucidate the
possible mechanism by which CIITA mediates gene suppres-
sion, efforts were undertaken to define the domain(s) within
CIITA that is responsible for the suppressive activity. Two
critical constructs were tested. One constitutes the N-terminal
one-third of CIITA [designated Flag CIITA(1-335)], and the
other represents the C-terminal two-thirds of CIITA [desig-
nated CIITA(334-1130)]. Each mutant, wild-type CIITA, or
empty vector pcDNA3 was cotransfected with col-CAT into
target cells. As shown in Fig. 3A, the collagen promoter was
suppressed by Flag CIITA(1-335) as efficiently as full-length
CIITA (lanes 2 to 4). In contrast, CIITA(334-1130) had little
effect on collagen promoter activation. Again, full-length CI-
ITA vigorously activated an MHC-II promoter (Fig. 3B, lane
3), but neither the N terminus nor the C terminus alone re-
sulted in MHC-II promoter activation. This is expected on the
basis of previous studies (11).
To map the region within the N-terminal 335 aa of CIITA
FIG. 3. The N-terminal 59 to 94 aa of CIITA is responsible for the inhibition of collagen 2(I) promoter activities. (A) The collagen 2(I) CAT
reporter gene or its empty vector, pGL3-CAT, was transiently cotransfected with the N terminus or C terminus of CIITA [designated Flag
CIITA(1-335) and CIITA(334-1130), respectively] or its empty vector, pcDNA3, into NIH 3T3 cells as described in the legend to Fig. 1. A portion
of the cell lysate was subjected to CAT assay for collagen 2(I) promoter activity. (B) DRA-Luc reporter gene or its empty vector, pGL3-Luc, was
transfected into the same cells as those described for panel A. Luciferase (Luc) activity was used to show DRA promoter activity. CAT (A) or
luciferase (B) activities were normalized based on the activity of the pGL3-CAT group (A) or the pGL3-Luc group (B), respectively. (C) A series
of CIITA deletion constructs are shown. AD, acidic domain; PST, proline-, serine-, and threonine-rich domain; GTP, GTP binding site; NES,
nuclear export sequence; BLS/NLS, nuclear localization sequence. (D) The experiment depicted was performed in a manner identical to that of
the experiment depicted in panel A. The collagen 2(I) CAT reporter gene or its empty vector, pGL3-CAT, was transiently cotransfected with
CIITA, its empty vector control, pcDNA3, or a series of C terminus deletion mutants, as depicted in the panel C. The results are expressed as
relative fold induction of CAT activity over the negative control pGL3-CAT basic vector. Error bars represent means 	 standard errors. Data
shown have been reproduced three times. (E) The collagen 2(I) CAT reporter gene was transiently cotransfected with empty vector, wild-type
(wt) CIITA, or CIITA(59-94).
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that is required for this suppressive activity, a series of CIITA
mutants representing nested deletions of approximately 30 aa
each were constructed (Fig. 3C). These mutants, wild-type
CIITA, or empty vector pcDNA3 were cotransfected with the
col-CAT reporter gene (Fig. 3D). Full-length CIITA sup-
pressed most of the collagen promoter activity (lane 3), as did
Flag CIITA(1-335) (lane 4). Further deletions of CIITA up to
Flag CIITA(1-94) still caused a similar degree of suppression;
however, the suppressive function was no longer observed with
Flag CIITA(1-58), which contains the final N-terminal 58 aa.
All of these deletion constructs were nonfunctional for the
MHC-II promoter, as expected (data not shown).
To more definitively show that residues 59 to 94 are impor-
tant for gene suppression, an internal deletion construct that
lacks these residues was constructed (Fig 3E). This construct,
CIITA(59-94), did not inhibit the collagen 2(I) promoter,
while wild-type CIITA did (compare lanes 2 and 3). Taken
together, the results shown in Fig. 3 strongly support the im-
portance of residues 59 to 94 in suppressing the collagen pro-
moter. It is noteworthy that a recent study shows that residues
518 to 642 of CIITA associate with NF-YB, while residues 218
to 335 associate with NF-YC (65). These residues lie outside of
the region (residues 59 to 94) defined here as being important
for gene suppression. This supports our earlier conclusion that
the squelching of NF-Y is not likely the primary mechanism by
which CIITA causes gene suppression.
CIITA residues 59 to 94 contain sequences that interact with
the CBP. CBP interacts with CIITA and enhances the expres-
sion of MHC-II genes. Although fine mapping of the CIITA
domain which interacts with CBP has not been performed, the
N-terminal portion of the molecule is known to be important
for this interaction (20, 30). Therefore, we tested if the inhi-
bition of collagen 2(I) promoter activity by CIITA is mediated
by the physical association of CIITA with CBP. According to
this model, CIITA would squelch CBP such that the protein is
unavailable for the activation of other CBP-dependent pro-
moters. Experiments were performed to determine whether
CBP interacts with the CIITA sequence that mediates gene
suppression. COS7 cells were cotransfected with full-length or
truncated forms of CIITA linked to the Flag epitope along
with a CBP expression vector or empty vector control. The
lysates were immunoprecipitated with anti-Flag antibodies to
bring down CIITA or its truncated variants. The immunopre-
cipitates were analyzed for the presence of CBP by anti-CBP
Western blotting. A fraction of the lysate was also tested for
the expression of CBP. As shown in Fig. 4, CBP was copre-
cipitated with full-length CIITA (compare lanes 1 and 2 of Fig.
4B) and Flag CIITA(1-94) but not Flag CIITA(1-58). These
results indicate that the CIITA domain important for interac-
tion with CBP corresponds to the domain important for the
inhibition of collagen 2(I) transcriptional activity.
The addition of exogenous CBP rescues collagen 2(I) pro-
moter from the suppressive effects of CIITA. To investigate the
biological significance of these physical interactions and to
determine if CBP is the target of CIITA-mediated gene sup-
pression, increasing doses of a CBP expression vector were
transfected into cells. The col-Luc (collagen promoter, lucif-
erase reporter) plasmid and the CIITA expression vector were
also cotransfected into these cells. The assumption is that if
CIITA sequesters CBP, then the addition of exogenous CBP
should overcome the suppressive function of CIITA. As shown
in Fig. 5A, CBP alone activated the collagen 2(I) promoter
activity in comparison to the empty vector control (lanes 1 and
2). The addition of CIITA significantly suppressed collagen
promoter activity (compare lanes 1 and 3). This suppression
was maintained in the presence of low levels of exogenously
expressed CBP (compare lane 2 to 4 or 5); however, it was
released by the addition of a higher quantity (2 g) of CBP
(lane 6). This indicates that additional CBP reverses the CIITA
inhibition of collagen 2(I) transcriptional activity, and CBP is
likely the target of CIITA. Together with the mapping data
shown in Fig. 4, these experiments strongly support the hy-
pothesis that CIITA is squelching CBP molecules, resulting in
gene suppression. To exclude the trivial explanation that CBP
overexpression downregulates the expression of exogenous
CIITA, equal amounts of CIITA were cotransfected with var-
ious amounts of CBP. As shown in Fig. 5B, the expression level
of CIITA was not altered by the absence or presence of various
amounts of CBP (compare lane 1 with 2, 3, or 4).
IFN- inhibition of promoter activity is associated with the
presence of CIITA. IFN- induces as well as suppresses gene
expression (6, 33). CIITA mediates the IFN- activation of
MHC-II genes, while this report finds that CIITA can suppress
gene expression. Therefore, it was of interest to determine
whether CIITA may be an underlying mediator of IFN--
induced gene suppression in cells that express CIITA. Inter-
estingly, the collagen 2(I) gene studied here is a well-known
target of IFN--mediated suppression (22, 28, 46).
To test the physiologic relevance of CIITA-mediated sup-
pression of the collagen 2(I) gene, we used a mutant cell line
that is selectively defective in CIITA expression. Normally,
IFN- induces the expression of CIITA in the parental fibro-
sarcoma 2fTGH cell line, which then leads to surface MHC-II
expression (37). G3A is an MHC-II-negative mutant derived
from 2fTGH, which was immunoselected for the lack of
MHC-II antigen expression (37). All other known components
FIG. 4. CBP interacts with CIITA at its N terminus. (A) COS7
cells (9  105) were cotransfected with 3 g of FlagCIITA or
FlagCIITA(1-58) or FlagCIITA(1-94) or its corresponding control vec-
tor, pcDNA3, and 3 g of CMV5-CBP or its empty vector, CMV5, as
indicated. Cells were lysed with 1.5 ml of RIPA buffer 36 h after
transfection, and 25 l of the samples was subjected to SDS–10%
polyacrylamide gel electrophoresis resolution. The expression of CBP
was analyzed by immunoblotting (IB) using the rabbit anti-CBP anti-
body. (B) The cell lysate described above was immunoprecipitated (IP)
with anti-Flag M2-agarose at 4°C overnight. The association of CBP
with wild-type FlagCIITA (lane 2) and mutant FlagCIITA(1-94) was
revealed by immunoblotting using the rabbit anti-CBP antibody.
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of an IFN- response are normal in this cell line, including the
functional IFN- receptor and members of the JAK/STAT1
pathway. The IFN- induction of IRF-1, guanylate binding
protein, and 
2-microglobulin is also normal (37). These re-
sults suggest that the defect in this cell line is specific to
MHC-II gene control. However, NF-Y and RFX proteins are
all found to be normal in G3A cells, indicating that the defect
is not in these DNA-binding transcription factors (10). When
CIITA was examined, its induction by IFN- was found to be
defective. Semiquantitative RT-PCR shows that the CIITA
level is approximately one-fiftieth that of 2fTGH (10). Defec-
tive CIITA induction by IFN- in this line is likely the basis for
the lack of MHC-II induction, as the reintroduction of CIITA
into this line restores MHC-II expression and causes MHC-II
promoters to assume an open configuration (61).
A comparison of responses in 2fTGH versus G3A cells pro-
vides a direct analysis of the physiologic role of CIITA upon
IFN- treatment. First, to determine the effect of IFN--in-
duced expression of endogenous CIITA on the transcriptional
activity of col-CAT, this reporter construct was transiently
transfected into 2fTGH in the presence or absence of IFN-.
IFN- repressed col-CAT activity (Fig. 6A, lanes 1 and 2),
albeit to a lesser extent than that of exogenously expressed
CIITA (lane 3). This may be due to the low level of CIITA that
is induced by IFN- in these cells compared to the higher level
derived from transfected CIITA. Mutant CIITA(1-94) also
downregulated col-CAT activity, but to a lesser extent than
wild-type CIITA, while CIITA(1-58) had no effect.
To determine if CIITA suppresses gene expression during
an IFN- response in a more physiologic system, an analysis
was performed in the CIITA-defective mutant cell line G3A.
In contrast to the 2fTGH cell line (Fig. 6B), treatment of these
cells with IFN- (lanes 1 and 2) did not result in suppression of
col-CAT expression. The introduction of CIITA restored
IFN- suppression of col-CAT activity in these cells (lanes 3
and 4). This strongly supports the contention that CIITA me-
diates IFN- suppression of promoter activity. As a control,
Fig. 6C shows that the addition of IFN- to the same culture of
G3A cells did not result in MHC-II promoter activation (com-
pare lanes 1 and 2). In contrast, the addition of CIITA resulted
in the induction of the MHC-II promoter. These studies show
that endogenous CIITA has dual activity, both as an inducer of
MHC-II promoters and as an inhibitor of the collagen 2(I)
promoter.
CIITA inhibits endogenous collagen 2(I) expression. To
further determine if endogenously expressed CIITA affects the
expression of endogenous collagen 2(I) gene expression,
2fTGH and G3A cells were treated with IFN- for 24 or 48 h.
As described above, the former has intact CIITA expression,
while G3A has a defect in the IFN- induction of CIITA; thus,
differences in these two lines in response to IFN- can be
attributed to endogenous CIITA. RT-PCR was performed to
examine endogenous collagen 2(I) transcript levels. The lin-
ear phase of amplification for each gene was preestablished
and used in all the experiments to avoid artifacts associated
with RT-PCR (see Materials and Methods). In addition, these
experiments were repeated three times, and they produced
consistent findings. In 2fTGH cells, IFN- suppressed collagen
2(I) without any effect on the housekeeping gene of GAPDH
(Fig. 7A, compare lane 1 with lanes 2 and 3). The transient
transfection of a CIITA expression construct also significantly
suppressed endogenous collagen 2(I) gene expression in the
absence of IFN- treatment.
A comparative study with the G3A cells shows that IFN-
failed to inhibit the expression of endogenous collagen 2(I) in
this mutant line (Fig. 7B, compare lane 1 with lanes 2 and 3).
To further specify the role of CIITA in this inhibitory pathway,
G3A cells were transiently or stably transfected with CIITA,
and the endogenous collagen 2(I) mRNA level was examined.
The appropriate control plasmid for the transient transfectant
is pcDNA3, while that for the stably transfected cell line is
pREP4. Exogenously introduced CIITA inhibited the expres-
sion of endogenous collagen 2(I) transcript (Fig. 7B, compare
lanes 4 to 5 and 6 to 7). Together, these experiments show that
CIITA suppresses the expression of the endogenous collagen
2(I) gene.
For the quantitative measurement of the changes depicted
in Fig. 7A and B, a new experiment similar to the one de-
scribed in the legend to Fig. 7A and B was performed. Total
FIG. 5. CBP relieves the inhibition of collagen 2(I) promoter ac-
tivities by CIITA. (A) Increasing amounts of CBP were cotransfected
with CIITA and/or carrier DNA, as depicted in the figure. The influ-
ence of CBP on CIITA-mediated suppression of the collagen promoter
was measured by comparing the collagen luciferase reporter gene
activity in the absence (lane 3) or presence (lane 4 to 6) of CBP. The
quantity of CBP used to transfect the cells are depicted in the figure.
These experiments were repeated three times. (B) COS7 cells (9 
105) were cotransfected with 3 g of FlagCIITA and various amounts
of CBP (1.5, 3.0, and 4.5 g for lanes 2, 3, and 4, respectively) or its
empty control vector, CMV5 (lane 1). CMV5 empty vector was also
added to lanes 1 to 3 such that the total amount of plasmid transfected
is the same in all of the samples. Cells were lysed with 1.5 ml of RIPA
buffer 36 h after transfection, and 25 l of the samples was subjected
to SDS–10% polyacrylamide gel electrophoresis resolution. The ex-
pression of Flag CIITA was analyzed by immunoblotting (IB) using
anti-Flag antibody.
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RNA from each sample was reverse transcribed and subse-
quently amplified by PCR in the presence of [-32P]dCTP. The
findings, shown in Fig. 7C and D, confirm the qualitative re-
sults from Fig. 7A and B. These results were quantitated and
plotted against the data from GAPDH-specific PCR-amplified
product shown in the lower panel of Fig. 7C and D.
Treatment of 2fTGH with IFN- caused a reduction of the
endogenous collagen 2(I) transcript, although in this experi-
ment the reduction is less obvious at the 24-h time point but is
apparent at the 48-h time point. The transient introduction of
CIITA into cells which have not been treated with IFN-
caused a 50% drop in collagen 2(I) transcript. This is found
for both 2fTGH and G3A cells (compare lane 4 to 5 in Fig. 7C
and D). This modest effect is likely attributed to the fact that
transient transfection can only introduce the transfected gene
in a portion of the cells. However, a G3A line which has been
stably transfected with CIITA shows a dramatic reduction of
collagen 2(I) transcript (Fig. 7D, lanes 6 and 7).
Additional promoters known to be inhibited by IFN- are
also inhibited by CIITA. In addition to genes coding for matrix
proteins such as collagen and fibronectin, IFN- is known to
suppress other cellular processes. The most notable examples
are the suppression of IL-4 production in TH2 cells (23) and
the inhibition of cell growth (2, 45). To determine whether
CIITA mediates suppression of genes which participate in al-
ternate cellular processes, transcriptional activity of the IL-4
promoter was assessed using the IL-4 CAT reporter construct
(Fig. 8A), the TK promoter using the TK-CAT construct (Fig.
8B), and the cyclin D1 promoter using CD1-Luc (Fig. 8C). All
promoters were tested as described for the collagen promoter,
except IL-4 CAT was tested in both the NIH 3T3 fibroblastic
line and the Jurkat T-cell line. The latter was used because
IL-4 is produced by cells of T-cell origin. Transcriptional ac-
tivities of all these promoters were suppressed by CIITA. To
further investigate if residues 59 to 94 of CIITA are important
for this suppression, NIH 3T3 cells were transfected with the
IL-4 CAT reporter gene along with wild-type CIITA or CIITA
(59-94), which lacks the CBP interaction domain. As shown
in Fig. 8A, CIITA(59-94) did not inhibit IL-4 promoter tran-
scriptional activity, while wild-type CIITA did (compare lanes
2 and 3). This demonstrates the importance of residues 59 to
94 in suppressing IL-4 promoter activity.
DISCUSSION
CIITA is a master regulator of MHC-II gene expression
through its interaction with DNA-binding transcription factors
that bind the X and Y elements of MHC-II promoters. Spe-
cifically, distinct or overlapping domains of CIITA are re-
quired for interactions with NF-YB–NF-YC, RFX5-RFXANK
and CREB (65). These are, respectively, proteins that recog-
nize the Y, X1, and X2 elements of a MHC-II promoter. Based
on these interactions, we propose that CIITA may serve as a
scaffold protein, very much in the same vein as scaffold pro-
teins which interact with members of the mitogen-activated
protein kinase pathways to achieve specific cellular effects and
not others (65). The original intent of this work was to deter-
mine if CIITA shares a unique property of other signaling
scaffold proteins, e.g., the sequestration of mitogen-activated
protein kinase members for signaling in one cellular pathway,
thus reducing their availability for other pathways. In the case
of transcription, squelching is thought to serve the same pur-
pose by titrating general transcription factors which are limit-
ing (44). We tested the possibility that CIITA may sequester
first-tier DNA-binding proteins and reduce the availability of
these proteins for the initiation of other transcripts. The initial
finding (Fig. 1) shows that CIITA simultaneously enhances the
transcription of an MHC-II promoter and reduces the tran-
scription of a collagen 2(I) promoter which contains a canon-
ical NF-Y binding site. However, two further tests show that
FIG. 6. The use of 2fTGH and G3A cells to delineate the physiologic importance of CIITA in IFN--mediated gene suppression. (A) The
experiment was performed as described in the legend Fig. 3, except 2fTGH cells were treated with 500 U of IFN-/ml (lanes 1 and 2) 24 h after
transfection. The inhibition of col-CAT activity by IFN- treatment in these cells is shown. This suppression is observed with CIITA or
CIITA(1-94) but not with CIITA(1-58). (B) G3A cells were used in place of 2fTGH cells, and the experiment was performed as for panel A.
col-CAT activity was not inhibited by IFN- treatment in G3A cells (lanes 1 and 2). The inclusion of exogenously expressed CIITA inhibited
col-CAT activity (lanes 3 and 4). (C) The DRA-Luc control shows that the addition of IFN- to the same culture of G3A cells did not result in
MHC-II promoter activation (compare lanes 1 and 2). In contrast, the addition of CIITA resulted in the induction of the MHC-II promoter. These
experiments were reproduced three times. Luc, luciferase; wt, wild type.
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the sequestration of NF-Y by CIITA is unlikely the primary
mechanism by which CIITA causes gene suppression. First, the
addition of NF-Y only modestly reverts gene repression. Sec-
ond, the minimal domain within CIITA that is required for this
repression is distinct from its interaction site with NF-Y (65).
In contrast, these same tests show that CBP is the target be-
cause the addition of CBP rescues the collagen 2(I) promoter
from CIITA-mediated repression. Furthermore, the minimal
domain required for CIITA-mediated gene repression and for
interaction with CBP is contained within the same 36 residues.
In composite, these results strongly support the model where
CIITA mediates gene repression via the sequestration of CBP
while enhancing MHC-II transcription by interaction with CBP
and the transcription factors that activate MHC-II promoters.
This is of relevance to the control of a number of genes,
including both immune and nonimmune genes. During the
second review of this paper, a recent report found that CIITA
sequesters p300 to cause the suppression of the IL-4 promoter
(52). Thus, the squelching of CBP and p300 may be a common
mechanism by which CIITA mediates gene suppression.
FIG. 7. IFN- treatment, or introduction of CIITA, reduced the expression of endogenous collagen 2(I) transcripts in 2fTGH cells. (A) Total
RNA was isolated from 2fTGH cells with or without IFN- treatment for 24 (lane 2) or 48 h (lane 3), or cells were transiently transfected with
empty vector (lane 4) or CIITA (lane 5). Total RNAs were subjected to amplification by RT-PCR with primers specific for the collagen 2(I) gene.
GAPDH was used as a control. (B) The experiment depicted in lanes 1 to 5 is the same as that depicted in panel A, except that G3A cells were
used. Additionally, both transient (lanes 4 and 5) and stably transfected (lanes 6 and 7) cells were analyzed. (C and D) Total RNAs (1.5 g),
prepared in a manner similar to that described for panels A and B, were reverse transcribed, and an aliquot of each sample was subjected to
amplification by hot-PCR with the collagen-specific primers in the presence of [-32P]dCTP. PCR samples were electrophoresed in nondenatured
polyacrylamide gel, autoradiographed, and quantitated using the NIH Image software (lower graphs). GAPDH was used as a control (second row
of the upper panel).
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One question that arises from the present study is why
CIITA cannot be recruited to the collagen promoter through
NF-Y sites and activate its gene expression. Instead, it sup-
presses collagen gene expression. Indeed, the work from our
lab and other laboratories shows that CIITA physically inter-
acts with NF-Y (25, 65) through a domain that is distinct from
the CBP-associative domain identified here (65). There are
several possible explanations. First, although the NF-Y site
exists on nearly 30% of promoters, the combinatorial influence
of NF-Y with adjacent and distal elements is likely to influence
how CIITA affects these promoters (60). As a matter of fact,
the transactivation of MHC-II promoters by CIITA is depen-
dent on the stereospecific alignment of the X-Y box binding
protein, RFX, CREB, and NF-Y (40, 65). The collagen pro-
moter does not contain adjacent promoter elements found in
MHC-II, and this is likely the reason why CIITA does not
activate the collagen gene. Otherwise, CIITA should have
more global effects on gene expression. Second, although in
vivo chromatin immunoprecipitation indirectly shows that CI-
ITA interacts with NF-Y on the MHC-II promoter (3, 38),
evidence is lacking that this occurs on the collagen promoter.
It is possible that without the appropriate juxtaposed promoter
elements this interaction between CIITA and NF-Y may not
be stabilized to occur in cells.
An examination of CIITA-mediated gene repression reveals
interesting physiologic relevance of this finding. The collagen
promoter which was used as the prototype promoter to study
CIITA-mediated gene repression turns out to be a primary
target of IFN--mediated gene repression (26, 27, 64). This led
to our hypothesis that CIITA may be a mediator of the well-
documented gene repression by IFN-. A comparison of the
wild-type 2fTGH line and its CIITA-defective variant, G3A,
shows that the lack of CIITA is associated with the lack of
IFN--mediated gene suppression. Direct evidence that CIITA
is involved in IFN--mediated gene repression was obtained
when CIITA reproduced the effects of IFN- in 2fTGH cells
and further caused promoter and endogenous gene repression
in G3A cells to a level similar to that of 2fTGH. Thus, CIITA
constitutes a novel pathway which contributes to IFN--medi-
ated gene suppression. An examination of three types of pro-
moters that are known targets of IFN- repression shows that
all can be repressed by CIITA. The three types of promoters
include those for (i) matrix proteins, with collagen as a proto-
type target; (ii) cytokines produced by the T helper subset,
TH2, exemplified by IL-4; and (iii) cell cycle genes important
for cell cycle progression, such as the thymidine kinase and
cyclin D1 genes. However, it is unlikely that CIITA is the only
molecule that mediates IFN- repression, since not all IFN--
responsive cells produce CIITA. Other mechanisms in addi-
tion to CIITA must also exert their effects to cause gene re-
pression upon IFN- treatment. Nonetheless, among cell types
that express CIITA, CIITA should constitute an important
mechanism by which gene repression is mediated.
The repression of gene products required for cell cycle pro-
gression by IFN- has been well documented in the literature
(2, 12, 45, 51, 63), stemming from the early observations that
IFN- treatment leads to cell cycle arrest. During our studies
of CIITA, we have noted that long-term transfectants express-
ing ectopic CIITA were difficult to obtain, and the rare clones
which did grow expressed a low level of CIITA. These obser-
vations are consistent with the notion that CIITA can repress
FIG. 8. CIITA suppresses other promoters. The effect of CIITA on the IL-4 promoter (A), the TK promoter (B), and the cyclin D1 promoter
(C) are shown. The IL-4 CAT reporter gene was transiently cotransfected with an empty vector (panel A, left-hand graph, lane 1), wild-type (wt)
CIITA (same graph, lane 2), or CIITA(59-94) (same graph, lane 3). The other two reporter constructs were only cotransfected with either CIITA
or an empty vector.
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certain genes important for cell cycle progression, thus reduc-
ing their proliferation and growth.
The repression of IL-4 by CIITA has been observed by
another group (23), and that study was performed with mice
where CIITA was introduced as a transgene into all cells. The
authors noted a decrease in IL-4 synthesis, which was not
observed in a mouse lacking MHC-II antigen expression. The
authors detected CIITA expression by RT-PCR in a T-cell-
enriched preparation and concluded that CIITA expression in
the T-cell fraction leads to decreased IL-4 production. During
the review of this paper, this group showed that the binding of
p300 by CIITA may be responsible for this suppression.
The repression of CBP function is particularly interesting
and of practical relevance because CBP is a critical HAT im-
portant for the accessibility of a large group of promoters (13,
41, 57, 59). Its role in transcriptional regulation explains much
of promoter accessibility and chromatin structure. Its quantity
is limiting and thus is a likely target of squelching by CIITA.
There is some information that CIITA may interact with other
members of the histone acetylase family, including the p300
family. It will be of interest to assess whether CIITA also
affects these other HAT members. From another practical
vantage point, CIITA is very effective in inhibiting the function
of CBP through protein-protein interaction. Considering that
the region necessary for CIITA interaction with CBP is likely
smaller than the 36 aa defined here, it is possible that peptido-
mimetics approaches based on this interaction may be em-
ployed to block the function of CBP. This potentially has
therapeutic benefits for cancer in general and for drug-related
acute leukemia where a fusion of the MLL gene to CBP occurs
(53).
In conclusion, this report has several novel findings. First, it
shows that CIITA can mediate the IFN- suppression of genes.
This represents a clever design by nature, where CIITA is used
to mediate both the upregulation of crucial immune genes and
the downregulation of genes that may be nonessential during
an IFN- response. Gene suppression by IFN- has been ob-
served by many, yet the mechanism is not well understood. Our
study provides a molecular basis for this suppression. Second,
the mechanism of this repression is through the squelching of
CBP. Another report has shown the squelching of p300 by
CIITA (52); thus, squelching represents a common mechanism
for CIITA-mediated gene repression. Third, this study finely
delineates the region of CIITA that interacts with and
squelches CBP. This delineation provides an important new
reagent: a small but potent molecule to inhibit CBP function.
Fourth, this study took advantage of the G3A mutant cell line
and revealed the suppression of the endogenous collagen gene
by the endogenous level of CIITA that is induced by IFN-. In
sum, this report should have significant impact on a number of
fields, and it interjects CIITA into several important areas of
research, including the study of IFN- repression, collagen
gene regulation, CBP function, cancer therapy through the
inhibition of CBP, and transcriptional squelching.
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